Cargando…
FGF19 and FGF21 for the Treatment of NASH—Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human
FGF19 and FGF21 analogues are currently in clinical development for the potential treatment of NASH. In Phase 2 clinical trials analogues of FGF19 and FGF21 decrease hepatic steatosis with up to 70% (MRI-PDFF) after 12 weeks and as early as 12–16 weeks of treatment an improvement in NASH resolution...
Autores principales: | Henriksson, Emma, Andersen, Birgitte |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783467/ https://www.ncbi.nlm.nih.gov/pubmed/33414764 http://dx.doi.org/10.3389/fendo.2020.601349 |
Ejemplares similares
-
FGF19 and FGF21: In NASH we trust
por: Talukdar, Saswata, et al.
Publicado: (2020) -
FGF19 subfamily members: FGF19 and FGF21
por: Dolegowska, Katarzyna, et al.
Publicado: (2019) -
Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho
por: Aaldijk, Alexandra S., et al.
Publicado: (2023) -
FGF21 and Cardiac Physiopathology
por: Planavila, Anna, et al.
Publicado: (2015) -
Fundamentals of FGF19 & FGF21 Action In Vitro and In Vivo
por: Adams, Andrew C., et al.
Publicado: (2012)